• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia.

作者信息

Razga Filip, Racil Zdenek, Machova Polakova Katerina, Buresova Lucie, Klamova Hana, Zackova Daniela, Dvorakova Dana, Polivkova Vaclava, Cetkovsky Petr, Mayer Jiri

机构信息

Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Jihlavska 20, 625 00, Brno, Czech Republic.

Institute of Hematology and Blood Transfusion, Prague, Czech Republic.

出版信息

Int J Hematol. 2011 Sep;94(3):303-306. doi: 10.1007/s12185-011-0924-6. Epub 2011 Sep 8.

DOI:10.1007/s12185-011-0924-6
PMID:21901397
Abstract
摘要

相似文献

1
The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia.人有机阳离子转运体1和ABCB1表达水平在初发慢性粒细胞白血病患者不同细胞群体中的预测价值
Int J Hematol. 2011 Sep;94(3):303-306. doi: 10.1007/s12185-011-0924-6. Epub 2011 Sep 8.
2
Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types.初发慢性髓性白血病患者三磷酸腺苷结合盒亚家族B成员1（ABCB1）mRNA表达的评估：不同细胞类型的作用
Leuk Lymphoma. 2011 Feb;52(2):331-4. doi: 10.3109/10428194.2010.533220. Epub 2010 Dec 6.
3
Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1.伊马替尼和达沙替尼耐药的发展：药物转运体 ABCB1、ABCC1、ABCG2、MVP 和 SLC22A1 的表达动态。
Leuk Lymphoma. 2011 Oct;52(10):1980-90. doi: 10.3109/10428194.2011.584005. Epub 2011 Jun 12.
4
Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib.多药耐药基因MDR1（ABCB1）的多态性可预测新诊断的慢性髓性白血病患者接受高剂量伊马替尼治疗时的分子耐药性。
Blood. 2010 Dec 23;116(26):6144-5; author reply 6145-6. doi: 10.1182/blood-2010-07-296954.
5
Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia.在没有人类有机阳离子转运体1（hOCT1）的情况下，达沙替尼仍可能有效摄取：对伊马替尼耐药慢性髓性白血病治疗的意义
Blood. 2008 Oct 15;112(8):3348-54. doi: 10.1182/blood-2007-10-116236. Epub 2008 Jul 31.
6
Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase.慢性期慢性髓性白血病患者对伊马替尼的分子反应及其与伊马替尼流入和流出转运体mRNA表达水平的相关性。
Indian J Med Res. 2015 Aug;142(2):175-82. doi: 10.4103/0971-5916.164250.
7
Predicting benefit from imatinib: are we close?
Leuk Lymphoma. 2014 Nov;55(11):2421-2. doi: 10.3109/10428194.2014.909041. Epub 2014 Apr 22.
8
Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.探讨慢性髓性白血病患者中摄取转运体 SLCO1B3 和外排转运体 ABCB1 的遗传多态性与伊马替尼药代动力学的关系。
Ther Drug Monit. 2011 Apr;33(2):244-50. doi: 10.1097/FTD.0b013e31820beb02.
9
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.对于在伊马替尼治疗下达到完全细胞遗传学缓解的慢性髓性白血病患者，其分子学反应的取得取决于是否有较好的依从性。
J Clin Oncol. 2010 May 10;28(14):2381-8. doi: 10.1200/JCO.2009.26.3087. Epub 2010 Apr 12.
10
Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice.在社区临床实践中，低ABCB1水平和高OCT1水平对慢性粒细胞白血病（CML）患者对伊马替尼的分子反应起有利作用。
Leuk Res. 2016 Dec;51:3-10. doi: 10.1016/j.leukres.2016.10.005. Epub 2016 Oct 12.

引用本文的文献

1
Identification of exosomal microRNAs and related hub genes associated with imatinib resistance in chronic myeloid leukemia.鉴定与慢性髓性白血病伊马替尼耐药相关的外泌体 microRNAs 和相关枢纽基因。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Dec;397(12):9701-9721. doi: 10.1007/s00210-024-03198-1. Epub 2024 Jun 25.
2
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.药物转运体OCTN1基因启动子中的单核苷酸多态性rs460089对接受伊马替尼治疗的慢性髓性白血病患者的无治疗缓解具有预后价值。
Leukemia. 2024 Feb;38(2):318-325. doi: 10.1038/s41375-023-02109-2. Epub 2023 Dec 21.
3

本文引用的文献

1
Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types.初发慢性髓性白血病患者三磷酸腺苷结合盒亚家族B成员1（ABCB1）mRNA表达的评估：不同细胞类型的作用
Leuk Lymphoma. 2011 Feb;52(2):331-4. doi: 10.3109/10428194.2010.533220. Epub 2010 Dec 6.
2
OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.OCT-1 功能随细胞谱系而变化，但不受 BCR-ABL 影响。
Haematologica. 2011 Feb;96(2):213-20. doi: 10.3324/haematol.2010.033290. Epub 2010 Oct 22.
3
The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population.
OCT-1 Expression in Patients with Chronic Myeloid Leukemia: A Comparative Analysis with Respect to Response to Imatinib Treatment.
慢性髓性白血病患者中OCT-1的表达：关于对伊马替尼治疗反应的比较分析
Indian J Hematol Blood Transfus. 2022 Oct;38(4):668-674. doi: 10.1007/s12288-022-01532-2. Epub 2022 Apr 11.
4
ABCB1 and BMI1 mRNA expression in patients with chronic myeloid leukemia: impact on imatinib efficacy.慢性髓性白血病患者中ABCB1和BMI1 mRNA表达：对伊马替尼疗效的影响
Blood Res. 2019 Mar;54(1):57-62. doi: 10.5045/br.2019.54.1.57. Epub 2019 Mar 21.
5
Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia.浅析 ABCB1/P-糖蛋白在慢性髓性白血病中的作用
Molecules. 2018 Jan 7;23(1):119. doi: 10.3390/molecules23010119.
6
Significance of OCT1 Expression in Acute Myeloid Leukemia.OCT1表达在急性髓系白血病中的意义
Pathol Oncol Res. 2017 Jul;23(3):665-671. doi: 10.1007/s12253-016-0161-7. Epub 2016 Dec 26.
7
Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?ABCB1过表达作为慢性粒细胞白血病的预测标志物：我们距离临床应用还有多远？
Leukemia. 2017 Jan;31(1):266-267. doi: 10.1038/leu.2016.266. Epub 2016 Oct 21.
慢性粒细胞白血病患者中人类有机阳离子转运体1（hOCT1）mRNA表达的评估受分析细胞群体中不同细胞类型比例的影响。
Am J Hematol. 2010 Jul;85(7):525-8. doi: 10.1002/ajh.21722.
4
hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.慢性髓性白血病中hOCT1转录水平和单核苷酸多态性作为伊马替尼反应的预测因素
Leukemia. 2010 Jun;24(6):1243-5. doi: 10.1038/leu.2010.86. Epub 2010 May 6.
5
Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib.OCT-1 蛋白的功能活性可预测接受伊马替尼治疗的慢性期慢性髓性白血病患者的长期预后。
J Clin Oncol. 2010 Jun 1;28(16):2761-7. doi: 10.1200/JCO.2009.26.5819. Epub 2010 Apr 26.
6
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.慢性髓性白血病：欧洲白血病网络概念与管理建议的更新
J Clin Oncol. 2009 Dec 10;27(35):6041-51. doi: 10.1200/JCO.2009.25.0779. Epub 2009 Nov 2.
7
Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.P-糖蛋白的组成型过表达而非乳腺癌耐药蛋白或有机阳离子转运体1，促成了K562细胞对伊马替尼耐药性的获得。
Pharm Res. 2008 Apr;25(4):827-35. doi: 10.1007/s11095-007-9376-3. Epub 2007 Oct 13.
8
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.大多数对伊马替尼反应欠佳的慢性粒细胞白血病患者OCT-1活性较低：更高剂量的伊马替尼可能会克服OCT-1活性低的负面影响。
Blood. 2007 Dec 1;110(12):4064-72. doi: 10.1182/blood-2007-06-093617. Epub 2007 Aug 30.
9
Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.摄取性药物转运体hOCT1的表达是慢性髓性白血病中对伊马替尼反应的重要临床决定因素。
Clin Pharmacol Ther. 2008 Feb;83(2):258-64. doi: 10.1038/sj.clpt.6100268. Epub 2007 Jun 13.
10
Active transport of imatinib into and out of cells: implications for drug resistance.伊马替尼进出细胞的主动转运：对耐药性的影响。
Blood. 2004 Dec 1;104(12):3739-45. doi: 10.1182/blood-2003-12-4276. Epub 2004 Aug 17.